CVS Health's near-certain 100% market-implied odds of beating Q2 2026 consensus estimates reflect its consistent outperformance, including four straight quarterly beats averaging 16.8% surprises, most recently delivering $2.57 EPS versus $2.21 expected in Q1. Positive Earnings ESP of +1.42% alongside Zacks Rank signals and modest consensus growth expectations around $1.85 EPS on $100 billion revenue further reinforce trader confidence ahead of the August 5 release. Recent full-year guidance raises, driven by Aetna medical loss ratio improvements and pharmacy benefit manager margins, underscore fundamental momentum. While tail risks such as adverse volume shifts or regulatory pressures in integrated segments could theoretically disrupt results, the combination of historical accuracy and pre-report optimism leaves limited scope for downside surprises in this skin-in-the-game consensus.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoWill CVS Health (CVS) beat quarterly earnings?
Will CVS Health (CVS) beat quarterly earnings?
>99% probabilità
$8,912 Vol.
$8,912 Vol.
5 ago 2026
>99% probabilità
$8,912 Vol.
$8,912 Vol.
5 ago 2026
As of market creation, CVS Health is estimated to release earnings on August 5, 2026. The Street consensus estimate for CVS Health’s non-GAAP EPS for the relevant quarter is $1.84 as of market creation. This market will resolve to "Yes" if CVS Health reports non-GAAP EPS greater than $1.84 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
CVS Health's near-certain 100% market-implied odds of beating Q2 2026 consensus estimates reflect its consistent outperformance, including four straight quarterly beats averaging 16.8% surprises, most recently delivering $2.57 EPS versus $2.21 expected in Q1. Positive Earnings ESP of +1.42% alongside Zacks Rank signals and modest consensus growth expectations around $1.85 EPS on $100 billion revenue further reinforce trader confidence ahead of the August 5 release. Recent full-year guidance raises, driven by Aetna medical loss ratio improvements and pharmacy benefit manager margins, underscore fundamental momentum. While tail risks such as adverse volume shifts or regulatory pressures in integrated segments could theoretically disrupt results, the combination of historical accuracy and pre-report optimism leaves limited scope for downside surprises in this skin-in-the-game consensus.
As of market creation, CVS Health is estimated to release earnings on August 5, 2026. The Street consensus estimate for CVS Health’s non-GAAP EPS for the relevant quarter is $1.84 as of market creation. This market will resolve to "Yes" if CVS Health reports non-GAAP EPS greater than $1.84 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Mercato aperto: Jul 23, 2026, 10:32 PM ET
Volume
$8,912Data di fine
5 ago 2026Mercato aperto
Jul 23, 2026, 10:32 PM ETFonte di risoluzione
https://seekingalpha.com/Resolver
0x65070BE91...Esito proposto: Yes
Nessuna contestazione
Esito finale: Yes
As of market creation, CVS Health is estimated to release earnings on August 5, 2026. The Street consensus estimate for CVS Health’s non-GAAP EPS for the relevant quarter is $1.84 as of market creation. This market will resolve to "Yes" if CVS Health reports non-GAAP EPS greater than $1.84 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
CVS Health's near-certain 100% market-implied odds of beating Q2 2026 consensus estimates reflect its consistent outperformance, including four straight quarterly beats averaging 16.8% surprises, most recently delivering $2.57 EPS versus $2.21 expected in Q1. Positive Earnings ESP of +1.42% alongside Zacks Rank signals and modest consensus growth expectations around $1.85 EPS on $100 billion revenue further reinforce trader confidence ahead of the August 5 release. Recent full-year guidance raises, driven by Aetna medical loss ratio improvements and pharmacy benefit manager margins, underscore fundamental momentum. While tail risks such as adverse volume shifts or regulatory pressures in integrated segments could theoretically disrupt results, the combination of historical accuracy and pre-report optimism leaves limited scope for downside surprises in this skin-in-the-game consensus.
As of market creation, CVS Health is estimated to release earnings on August 5, 2026. The Street consensus estimate for CVS Health’s non-GAAP EPS for the relevant quarter is $1.84 as of market creation. This market will resolve to "Yes" if CVS Health reports non-GAAP EPS greater than $1.84 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Volume
$8,912Data di fine
5 ago 2026Mercato aperto
Jul 23, 2026, 10:32 PM ETFonte di risoluzione
https://seekingalpha.com/Resolver
0x65070BE91...Esito proposto: Yes
Nessuna contestazione
Esito finale: Yes
CVS Health's near-certain 100% market-implied odds of beating Q2 2026 consensus estimates reflect its consistent outperformance, including four straight quarterly beats averaging 16.8% surprises, most recently delivering $2.57 EPS versus $2.21 expected in Q1. Positive Earnings ESP of +1.42% alongside Zacks Rank signals and modest consensus growth expectations around $1.85 EPS on $100 billion revenue further reinforce trader confidence ahead of the August 5 release. Recent full-year guidance raises, driven by Aetna medical loss ratio improvements and pharmacy benefit manager margins, underscore fundamental momentum. While tail risks such as adverse volume shifts or regulatory pressures in integrated segments could theoretically disrupt results, the combination of historical accuracy and pre-report optimism leaves limited scope for downside surprises in this skin-in-the-game consensus.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti